Arvin Halim1, Heather N Burney2, Xiaochun Li2, Yang Li2, Claudia Tomkins3, Andrew M Siedlecki4, Tzong-Shi Lu4, Sahir Kalim5, Ravi Thadhani6, Sharon Moe1, Stephen M S Ting7, Daniel Zehnder8, Thomas F Hiemstra9, Kenneth Lim1. 1. Division of Nephrology and Hypertension, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. 2. Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana. 3. Biochemistry Department, Kettering General Hospital NHS Foundation Trust, Kettering, United Kingdom. 4. Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 5. Nephrology Division, Massachusetts General Hospital, Boston, Massachusetts. 6. Mass General Brigham, Harvard Medical School, Massachusetts. 7. Department of Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. 8. Department of Nephrology and Department of Acute Medicine, North Cumbria University Hospital NHS Trust, Carlisle, United Kingdom. 9. School of Clinical Medicine, University of Cambridge; Clinical Trials Unit (CTU), Addenbrooke's Hospital, Cambridge, United Kingdom.
Abstract
Background: Fibroblast growth factor 23 (FGF23) is a bone-derived phosphatonin that is elevated in chronic kidney disease (CKD) and has been implicated in the development of cardiovascular disease. It is unknown whether elevated FGF23 in CKD is associated with impaired cardiovascular functional capacity, as assessed by maximum exercise oxygen consumption (VO2Max). We sought to determine whether FGF23 is associated with cardiovascular functional capacity in patients with advanced CKD and after improvement of VO2Max by kidney transplantation. Methods: We performed secondary analysis of 235 patients from the Cardiopulmonary Exercise Testing in Renal Failure and After Kidney Transplantation (CAPER) cohort, which recruited patients with stage 5 CKD who underwent kidney transplantation or were waitlisted and hypertensive controls. All patients underwent cardiopulmonary exercise testing (CPET) and echocardiography and were followed longitudinally for 1 year after study enrollment. Results: Patients across FGF23 quartiles differed in BMI (P=0.004) and mean arterial pressure (P<0.001) but did not significantly differ in sex (P=0.5) or age (P=0.08) compared with patients with lower levels of FGF23. Patients with higher FGF23 levels had impaired VO2Max (Q1: 24.2±4.8 ml/min per kilogram; Q4: 18.6±5.2 ml/min per kilogram; P<0.001), greater left ventricular mass index (LVMI; P<0.001), reduced HR at peak exercise (P<0.001), and maximal workload (P<0.001). Kidney transplantation conferred a significant decline in FGF23 at 2 months (P<0.001) before improvement in VO2Max at 1 year (P=0.008). Multivariable regression modeling revealed that changes in FGF23 was significantly associated with VO2Max in advanced CKD (P<0.001) and after improvement after kidney transplantation (P=0.006). FGF23 was associated with LVMI before kidney transplantation (P=0.003), however this association was lost after adjustment for dialysis status (P=0.4). FGF23 was not associated with LVMI after kidney transplantation in all models. Conclusions: FGF23 levels are associated with alterations in cardiovascular functional capacity in advanced CKD and after kidney transplantation. FGF23 is only associated with structural cardiac adaptations in advanced CKD but this was modified by dialysis status, and was not associated after kidney transplantation.
Background: Fibroblast growth factor 23 (FGF23) is a bone-derived phosphatonin that is elevated in chronic kidney disease (CKD) and has been implicated in the development of cardiovascular disease. It is unknown whether elevated FGF23 in CKD is associated with impaired cardiovascular functional capacity, as assessed by maximum exercise oxygen consumption (VO2Max). We sought to determine whether FGF23 is associated with cardiovascular functional capacity in patients with advanced CKD and after improvement of VO2Max by kidney transplantation. Methods: We performed secondary analysis of 235 patients from the Cardiopulmonary Exercise Testing in Renal Failure and After Kidney Transplantation (CAPER) cohort, which recruited patients with stage 5 CKD who underwent kidney transplantation or were waitlisted and hypertensive controls. All patients underwent cardiopulmonary exercise testing (CPET) and echocardiography and were followed longitudinally for 1 year after study enrollment. Results: Patients across FGF23 quartiles differed in BMI (P=0.004) and mean arterial pressure (P<0.001) but did not significantly differ in sex (P=0.5) or age (P=0.08) compared with patients with lower levels of FGF23. Patients with higher FGF23 levels had impaired VO2Max (Q1: 24.2±4.8 ml/min per kilogram; Q4: 18.6±5.2 ml/min per kilogram; P<0.001), greater left ventricular mass index (LVMI; P<0.001), reduced HR at peak exercise (P<0.001), and maximal workload (P<0.001). Kidney transplantation conferred a significant decline in FGF23 at 2 months (P<0.001) before improvement in VO2Max at 1 year (P=0.008). Multivariable regression modeling revealed that changes in FGF23 was significantly associated with VO2Max in advanced CKD (P<0.001) and after improvement after kidney transplantation (P=0.006). FGF23 was associated with LVMI before kidney transplantation (P=0.003), however this association was lost after adjustment for dialysis status (P=0.4). FGF23 was not associated with LVMI after kidney transplantation in all models. Conclusions: FGF23 levels are associated with alterations in cardiovascular functional capacity in advanced CKD and after kidney transplantation. FGF23 is only associated with structural cardiac adaptations in advanced CKD but this was modified by dialysis status, and was not associated after kidney transplantation.
Authors: Stephen M S Ting; Hasan Iqbal; Hemali Kanji; Thomas Hamborg; Nicolas Aldridge; Nithya Krishnan; Chris H E Imray; Prithwish Banerjee; Rosemary Bland; Robert Higgins; Daniel Zehnder Journal: J Am Soc Nephrol Date: 2013-11-14 Impact factor: 10.121
Authors: Stephen M S Ting; Thomas Hamborg; Gordon McGregor; David Oxborough; Kenneth Lim; Sudheer Koganti; Nicolas Aldridge; Chris Imray; Rosemary Bland; Simon Fletcher; Nithya S Krishnan; Robert M Higgins; Jonathan Townend; Prithwish Banerjee; Daniel Zehnder Journal: Am J Kidney Dis Date: 2015-04-18 Impact factor: 8.860
Authors: Kenneth Lim; Stephen M S Ting; Thomas Hamborg; Gordon McGregor; David Oxborough; Claudia Tomkins; Dihua Xu; Ravi Thadhani; Gregory Lewis; Rosemary Bland; Prithwish Banerjee; Simon Fletcher; Nithya S Krishnan; Robert Higgins; Daniel Zehnder; Thomas F Hiemstra Journal: JAMA Cardiol Date: 2020-04-01 Impact factor: 14.676
Authors: Despina Sitara; Mohammed S Razzaque; René St-Arnaud; Wei Huang; Takashi Taguchi; Reinhold G Erben; Beate Lanske Journal: Am J Pathol Date: 2006-12 Impact factor: 4.307
Authors: Rajan K Patel; Patrick B Mark; Nicola Johnston; Ellon McGregor; Henry J Dargie; Alan G Jardine Journal: Clin J Am Soc Nephrol Date: 2008-07-23 Impact factor: 8.237